Huayu Pharmaceutical (6621) announced on the 6th that it has officially stepped into the pet medical market, aiming at more than 30 billion pet cancer screening business opportunities worldwide.
Huayu Pharmaceutical has its own tumor marker DR-70 for postoperative monitoring of human colorectal cancer, and has cooperated with Asia’s largest veterinary hospital to confirm that DR-70 can also be used for cancer detection in dogs. After Huayu Pharmaceutical’s unique patented reagent formula was tested, and after comparing the blood samples of hundreds of tumor and healthy dogs, it was successfully confirmed that a high concentration of DR-70 could be detected in the blood of tumor dogs, with a sensitivity and specificity of more than 90%, which has excellent detection and application potential.
In recent years, the health awareness of companion animals at home and abroad has risen, with the increase in their number, pet anthropomorphism and family structure changes and other factors, awakening the global wave of attention to pet health care, and the number of pets in the world is showing a positive growth trend.
DR-70 is a type of fibrinogen degradation product (FDP), and when cancer cells grow and expand, they will compress the surrounding normal tissues, causing the cells to release a large amount of DR-70 into the bloodstream. By measuring the concentration of DR-70 in the blood, it is possible to diagnose the occurrence of cancer at an early stage or to assess the degree of cancer progression. DR-70 was approved by the U.S. FDA in 2008 for a new generation of tumor markers for postoperative adjuvant monitoring of colorectal cancer, and it is also the only tumor marker approved for colorectal cancer 25 years after the U.S. FDA approved CEA for colorectal cancer in 1983. In 2013, Huayu Pharmaceutical obtained the technology transfer authorization of DR-70 AMDL, outsourced the production and manufacturing of Shiji (7595), and obtained the second-class medical device license in Taiwan in 2014. At present, it has been used in 12 medical centers in China, and is often used in colorectal surgery, oncology or health examination. Due to the high similarity between the mechanism and pathological changes of dog cancer and that of humans, the company’s innovative R&D and experimental breakthroughs have successfully observed the high performance of DR-70 in the blood of dogs with cancer, confirming its diagnostic value. Similar observations have been made in the diagnosis of cancer in cats.
Original news: https://ctee.com.tw/livenews/aj/ctee/A88131002021100620163903
